Allogene Therapeutics Inc (NASDAQ:ALLO) has a beta value of 0.81 and has seen 3.96 million shares traded in the last trading session. The company, currently
During the recent session, Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares were 0.46 million, with the beta value of the company hitting 0.80. At the last
In the last trading session, 2.81 million shares of the Allogene Therapeutics Inc (NASDAQ:ALLO) were traded, and its beta was 0.82. Most recently the company’s
In the last trading session, 2.92 million shares of the Allogene Therapeutics Inc (NASDAQ:ALLO) were traded, and its beta was 0.83. Most recently the company’s
Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares stood at 3.08 million during the last session, with the company’s beta value hitting 0.83. At the close of
In the last trading session, 2.27 million Allogene Therapeutics Inc (NASDAQ:ALLO) shares changed hands as the company’s beta touched 0.89. With the company’s per share
In the latest trading session, 0.45 million Allogene Therapeutics Inc (NASDAQ:ALLO) shares changed hands as the company’s beta touched 0.89. With the company’s most recent
In last trading session, Allogene Therapeutics Inc (NASDAQ:ALLO) saw 2.52 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price
Allogene Therapeutics Inc (NASDAQ:ALLO) has a beta value of 0.83 and has seen 2.6 million shares traded in the last trading session. The company, currently
Allogene Therapeutics Inc (NASDAQ:ALLO) has a beta value of 0.83 and has seen 3.16 million shares traded in the last trading session. The company, currently
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
